Half-Year 2022 Financial and Clinical Trials Update

Herceptin Global sales CHFbn CER growth -16% Regional sales CER growth US -27% 3.6 Europe -11% 3.0 Japan -28% 2.4 1.8 1.2 International -11% 0.6 0.0 HY 19 HY 20 HY 21 HY 22 HY 2022 sales of CHF 1,179m • US: Biosimilar erosion slowing; Switching of patients with residual disease to Kadcyla; Cannibalization from Phesgo • EU: Biosimilar erosion slowing; Switching of patients with residual disease to Kadcyla; Cannibalization from Phesgo • Japan: Decline due to biosimilars International: Decline due to biosimilars CER-Constant Exchange Rates Roche 175

View entire presentation